Dosing the first patient in our Phase 1/2 trial of NEO-811 in renal cell carcinoma marks a pivotal inflection point for Neomorph, representing the first clinical evaluation of an asset from our ...

In this video, Elizabeth Plimack, MD, MS, FASCO, Deputy Director at Fox Chase Cancer Center, discusses current treatments for ...

In a groundbreaking development for cancer treatment, Neomorph, a local biotech firm, has begun clinical trials for its innovative molecular glue, NEO-811. This nove ...

The first patient dosing in the Phase 1/2 trial represents a crucial step in assessing NEO-811's efficacy and safety. The Phase 1/2 NEO-811-101 trial is a first-in-human, open-label study designed to ...

Stage 2 clear cell renal cell carcinoma is typically curable, especially when detected early. Surgery remains the cornerstone ...

The US Food and Drug Administration (FDA) has approved belzutifan (Welireg) for adults with advanced renal cell carcinoma following progression on a PD-1/L1 inhibitor and a vascular endothelial growth ...

Ferroptosis, a regulated cell death mechanism, is emerging as a promising target for cancer therapy. The process is mediated by the activity of acyl-CoA synthetase family member 4 (ACSL4) protein.

An Italian study published in Nature Medicine provides compelling evidence that fecal microbiota transplantation (FMT) can ...

Ferroptosis, a newly discovered regulated cell death mechanism is recognized for its role in cancer therapies. However, ferroptosis regulation in renal cancer cells is not yet established. In this ...

Stage 3 RCC involves tumor growth beyond the kidney, affecting nearby tissues or lymph nodes, but not distant organs. Diagnosis includes imaging, biopsy, and molecular testing to guide treatment ...